Intrahepatic cholangiocarcinoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1, iCCA treated between Jan, 2011 and Dec, 2020 (for 10 years) 2, Surgical resection as a first line therapy 3, Patients histologically diagnosed as iCCA 4, iCCA gross type was MF (mass forming type) or MF+PI (bile duct invasion type) 5, Patients who were more than 20 years old at the time of surgery 6, Contrast-enhanced CT or MRI was performed within 1 month before hepatectomy
Exclusion criteria
Exclusion criteria: 1, Patients with other synchronous or metachronous cancer 2, Patients who received preoperative local therapy (TACE,RF,radiotherapy,etc.) or preoperative chemotherapy 3, Intraductal papillary neoplasm of the bile duct (IPNB) cases are excluded 4, Combined hepatocellular-cholangiocarcinoma cases are excluded 5, Perihilar cholangiocarcinoma cases are excluded 6, Patients who died within 90-days after surgery because of operative complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival rates, Disease-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymph node metastasis, Resection margin | — |
Countries
Japan,Asia(except Japan)
Contacts
Kanazawa University Department of Hepato-Biliary-Pancreatic Surgery and Transplantation